Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …
decades ago, and activating RET rearrangements and mutations have since been identified …
[HTML][HTML] Clinical and translational implications of RET rearrangements in non–small cell lung cancer
Since the discovery in 2012 of rearranged during transfection proto-oncogene gene (RET)
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …
rearrangements in NSCLC, at least 12 different fusion variants have been identified, with …
Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: a meta-analysis of approximately 29,000 cancer …
M Totzeck, RI Mincu, S Mrotzek… - European journal of …, 2018 - journals.sagepub.com
Background Targeted therapy with tyrosine kinase inhibitors with anti-vascular endothelial
growth factor activity improves survival of cancer patients. Cardiovascular complications are …
growth factor activity improves survival of cancer patients. Cardiovascular complications are …
[HTML][HTML] Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
E Rulli, F Ghilotti, E Biagioli, L Porcu… - British journal of …, 2018 - nature.com
Background The evaluation of the proportional hazards (PH) assumption in survival analysis
is an important issue when Hazard Ratio (HR) is chosen as summary measure. The aim is to …
is an important issue when Hazard Ratio (HR) is chosen as summary measure. The aim is to …
Antiangiogenic therapies in non-small-cell lung cancer
A Alshangiti, G Chandhoke, PM Ellis - Current Oncology, 2018 - mdpi.com
Angiogenesis is frequent in non-small-cell lung cancer (NSCLC) and is associated with
more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic …
more aggressive disease. Many clinical trials have evaluated the addition of antiangiogenic …
Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer …
Abstract Development and formulation of an efficient and safe therapeutic regimen for
cancer theranostics are dynamically challenging. The use of mono-therapeutic cancer …
cancer theranostics are dynamically challenging. The use of mono-therapeutic cancer …
Combined treatment with apatinib and docetaxel in A549 xenograft mice and its cellular pharmacokinetic basis
Apatinib, a small-molecule inhibitor of VEGFR-2, has attracted much attention due to its
encouraging anticancer activity in third-line clinical treatment for many malignancies …
encouraging anticancer activity in third-line clinical treatment for many malignancies …
Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second …
Purpose Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3
trial for patients with Stage IV non-small cell lung cancer after standard platinum-based …
trial for patients with Stage IV non-small cell lung cancer after standard platinum-based …
[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung cancer, 2018 - Elsevier
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
Design, synthesis and preclinical evaluation of 5-methyl-N4-aryl-furo [2, 3-d] pyrimidines as single agents with combination chemotherapy potential
RKV Devambatla, S Choudhary, M Ihnat… - Bioorganic & Medicinal …, 2018 - Elsevier
The design, synthesis and biological evaluation of 4-substituted 5-methyl-furo [2, 3-d]
pyrimidines is described. The Ullmann coupling of 5-methyl-furo [2, 3-d] pyrimidine with aryl …
pyrimidines is described. The Ullmann coupling of 5-methyl-furo [2, 3-d] pyrimidine with aryl …